Successful use of Upadacitinib in the child patient with very early onset of ulcerative colitis and refractory to therapy

Ulcerative colitis is a chronic relapsing inflammatory disease of the colon with continuous spread of lesions from the rectum in the proximal direction. The etiology of the disease is unknown, but it is assumed to be developed as a result of a combination of several factors. The clinical picture is often similar to the picture of intestinal infection, which complicates the timely diagnosis of the disease, especially in children. Refractory to standard therapy limits therapeutic options and increases the frequency of surgical interventions. However, the emergence of new drugs, such as upadacitinib, opens up new opportunities for treating such patients and studying the effectiveness of therapy. We present a case of successful treatment of ulcerative colitis with upadacitinib in a child with the onset of the disease at the age of 6 months. The purpose of the description is to show the possibilities of using the janus kinase blocker Upadacitinib in severe ulcerative colitis in a child with a very early onset of the disease and without effect from previous therapy. The importance of early diagnosis and therapy is emphasized.

Contribution:
Usoltseva O.V., Potapov A.S., Anushenko A.O., Vinokurova A.V., Krasnovidova A.E., Zenkova K.I., Movsisyan G.B. — concept and design of the study;
Usoltseva O.V. — collection and processing of the material;
Usoltseva O.V., Vinokurova A.V. — statistical processing of the material;
Usoltseva O.V. — writing the text;
Potapov A.S. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: July 12, 2024
Accepted: August 07, 2024
Published: September 16, 2024

1. Le Berre C., Honap S., Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023; 402(10401): 571–84. https://doi.org/10.1016/S0140-6736(23)00966-2

2. Wallace K.L., Zheng L.B., Kanazawa Y., Shih D.Q. Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 2014; 20(1): 6–21. https://doi.org/10.3748/wjg.v20.i1.6

3. Törüner M., Ünal N.G. Epigenetics of inflammatory bowel diseases. Turk. J. Gastroenterol. 2023; 34(5): 437–48. https://doi.org/10.5152/tjg.2023.22515

4. Shamriz O., Mizrahi H., Werbner M., Shoenfeld Y., Avni O., Koren O. Microbiota at the crossroads of autoimmunity. Autoimmun. Rev. 2016; 15(9): 859–69. https://doi.org/10.1016/j.autrev.2016.07.012

5. Miyoshi J., Chang E.B. The gut microbiota and inflammatory bowel diseases. Transl. Res. 2017; 179: 38–48. https://doi.org/10.1016/j.trsl.2016.06.002

6. Herrera-de Guise C., Varela E., Sarrabayrouse G., Pozuelo Del Río M., Alonso V.R., Sainz N.B., et al. Gut microbiota composition in long-remission ulcerative colitis is close to a healthy gut microbiota. Inflamm. Bowel. Dis. 2023; 29(9): 1362–9. https://doi.org/10.1093/ibd/izad058

7. Smirnova G.I., Mulenkova A.V., Susloparova P.S., Korsunsky A.A. Changes in the gut microbiota in autism in children: pathogenetic significance and ways of correction. Rossiyskiy pediatricheskiy zhurnal. 2023; 26(5): 360–7. https://doi.org/10.46563/1560-9561-2023-26-5-360-367 https://elibrary.ru/dhofeq (in Russian)

8. Kim S., Jung Y., Lee S.B., Oh H.S., Hong S.N. Gut microbial signatures in clinically stable ulcerative colitis according to the mucosal state and associated symptoms. J. Gastroenterol. Hepatol. 2024; 39(2): 319–27. https://doi.org/10.1111/jgh.16434

9. Puca P., Capobianco I., Coppola G., Di Vincenzo F., Trapani V., Petito V., et al. Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease. Int. J. Mol. Sci. 2024; 25(5): 2789. https://doi.org/10.3390/ijms25052789

10. Aloi M., Lionetti P., Barabino A., Guariso G., Costa S., Fontana M., et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 2014; 20(4): 597-605. https://doi.org10.1097/01.MIB.0000442921.77945.09

11. Sandborn W.J., Ghosh S., Panes J., Schreiber S., D’Haens G., Tanida S., et al. Efficacy of Upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020; 158(8): 2139–49.e14. https://doi.org10.1053/j.gastro.2020.02.030

12. Baker K.F., Isaacs J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann. Rheum. Dis. 2018; 77(2): 175–87. https://doi.org10.1136/annrheumdis-2017-211555

13. Parmentier J.M., Voss J., Graff C., Schwartz A., Argiriadi M., Friedman M., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018: 2: 23. https://doi.org10.1186/s41927-018-0031-x

14. Dalal R.S., Kallumkal G., Cabral H.J., Bachour S., Barnes E.L., Allegretti J.R. Clinical and endoscopic outcomes after upadacitinib induction for ulcerative colitis: a multicenter retrospective cohort study. Inflamm. Bowel. Dis. 2024; 30(7): 1207–10. https://doi.org/10.1093/ibd/izad155

15. Miyatani Y., Choi D., Choi N.K., Rubin D.T. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn’s disease. Dig. Dis. Sci. 2024; 69(2): 355–9. https://doi.org/10.1007/s10620-023-08182-y

16. Loftus E.V. Jr., Colombel J.F., Takeuchi K., Gao X., Panaccione R., Danese S. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin. Gastroenterol. Hepatol. 2023; 21(9): 2347–58.e6. https://doi.org/10.1016/j.cgh.2022.11.029

17. D’Haens G., Panés J., Louis E., Lacerda A., Zhou Q., Liu J., et al. upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST extension study. Clin. Gastroenterol. Hepatol. 2022; 20(10): 2337–2346.e3. https://doi.org10.1016/j.cgh.2021.12.030

18. Potapov A., Vinokurova A., Pushkareva A., Prokhorenkova M., Anushenko O., Fisenko A. Use of upadacitinib in refractory paediatric inflammatory bowel disease in: a single-center cohort study. J. Crohn Colitis. 2024; 18(Suppl. 1): i1148 https://doi.org/10.1093/ecco-jcc/jjad212.0720

19. Collen L.V. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn’s disease. Inflamm. Bowel. Dis. 2023; 29(7): 1175–6. https://doi.org10.1093/ibd/izad048

20. Kontaki E., Merchant A., Gaynor E. Efficacy and safety of Upadacitinib in moderate to severe paediatric Crohns disease and ulcerative colitis in a tertiary Paediatric IBD (PIBD) centre – A case series. J. Crohn Colitis. 2024; 18(Suppl. 1): i986. https://doi.org/10.1093/ecco-jcc/jjad212.0624

21. Wang F., Sun L., Wang S., Davis J.M., Matteson E.L., Murad M.H., et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin. Proc. 2020; 95(7): 1404–19. https://doi.org/10.1016/j.mayocp.2020.01.039

22. Mohamed M.F., Jungerwirth S., Asatryan A., Jiang P., Othman A.A. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br. J. Clin. Pharmacol. 2017; 83(10): 2242–8. https://doi.org/10.1111/bcp.13329

23. Peyrin-Biroulet L., Panaccione R., Louis E., Atreya R., Rubin D.T., Lindsay J.O., et al. Upadacitinib achieves clinical and endoscopic outcomes in Crohn’s disease regardless of prior biologic exposure. Clin. Gastroenterol. Hepatol. 2024; S1542-3565(24)00253-2. https://doi.org/10.1016/j.cgh.2024.02.026

24. Berinstein J.A., Karl T., Patel A., Dolinger M., Barrett T.A., Ahmed W., et al. Effectiveness of Upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am. J. Gastroenterol. 2024. https://doi.org/10.14309/ajg.0000000000002674

25. Miller M., Patel A.S., Pasternak B. Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis. JPGN Rep. 2024; 5(2): 197–9. https://doi.org/10.1002/jpr3.12067

26. Santacroce G., Zammarchi I., Tan C.K., Coppola G., Varley R., Ghosh S., et al. Present and future of endoscopy precision for inflammatory bowel disease. Dig. Endosc. 2024; 36(3): 292–304. https://doi.org/10.1111/den.14672